Colorectal Cancer

Tumor Inflammation Drives Early Resistance to KRAS Drugs, Study Shows

Blocking the tumor‑intrinsic kinase TBK1 restored sensitivity to KRAS inhibitors in preclinical models, pointing to a combination strategy for clinical testing.